Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ketamine for treatment-resistant depression: biomarkers of response and relapse
2016-001715-21Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by UZ Leuven. Primary endpoints: Relief of depressive symptoms and Biomarkers of response and relapse. Started Jul 2016; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on 2016-001715-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001715-21.